Informations

01 What distinguishes lerociclib’s molecular design and mechanism from traditional CDK4/6 inhibitors? Professor Sun Tao: As we know, CDK4/6 inhibitors combined with endocrine therapy are established as a standard first-line…

Editor’s Note: The China National Medical Products Administration (NMPA) has officially approved the novel CDK4/6 inhibitor (CDK4/6i) Lerociclib for two indications in adult patients with hormone receptor–positive, HER2–negative (HR+/HER2-) locally…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) play a pivotal role in the treatment of HR+/HER2– advanced breast cancer (ABC). However, their efficacy and safety profiles vary across different agents. There remains…

Introduction CDK4/6 inhibitors (CDK4/6i) have become the cornerstone of standard therapy for patients with HR+/HER2- advanced breast cancer. However, differences in efficacy and safety profiles exist among currently approved CDK4/6…

Editor’s Note: On May 29, 2025, China’s National Medical Products Administration (NMPA) simultaneously approved Lerociclib (汝佳宁®, Lerociclib) for two indications in adult patients with hormone receptor–positive (HR+), human epidermal growth…

High Selectivity, High Penetration — Lerociclib Demonstrates Distinctive Potency Oncology Frontier: On May 29, Lerociclib received NMPA approval for dual indications—first-line and second-line treatment of HR+/HER2- advanced breast cancer. Based…

Message from Prof. Qingyuan Zhang: “Patients with HR+/HER2– advanced breast cancer have an urgent need for more effective and tolerable therapies. As a structurally optimized new-generation CDK4/6 inhibitor, Lerociclib has…

This approval signifies that China’s HR+/HER2– breast cancer treatment has entered a new era. Now, just over three months later, the first clinical prescriptions for Lerociclib in combination with aromatase…